The Valley Desk

Clinical trial reportJAMA network openPublished

Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Thomas Jefferson University. Affiliation source

Publication record

Type
Clinical trial report
Venue
JAMA network open
Published
Subject terms
Humans; Adenocarcinoma; Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms; Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Adult; Aged; Middle Aged; Female
PubMed ID
36602796
PubMed Central ID
PMC9856813
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal